First Read: Olympus Corporation "Acquiring shares of Israel-based BioProtect"

Research evidence excerpt

First Read: Olympus Corporation "Acquiring shares of Israel-based BioProtect"

Global Research

26 May 2026ab

First Read

EquitiesOlympus Corporation

Acquiring shares of Israel-based BioProtect Japan

Medical Supplies

12-month rating Neutral

Will contribute to expansion of urology field product lineup

Olympus announced (Link) after the market close on 26 May that it will acquire the 12m price target ¥1,760.0

shares of Israel-based medical device manufacturer BioProtect. The acquisition price is

US$270mn (approximately ¥43.3bn based on a forex rate of ¥160.4/$), with the share

Price (26 May 2026) ¥1,776

acquisition scheduled for 1 June 2026. Part of the acquisition consideration will be

retained for a certain period, with completion expected by the end of June 2026, subject RIC: 7733.T BBG: 7733 JP

to closing conditions being met. BioProtect specializes in the BioProtect Balloon Implant Trading data and key metrics

System, a biodegradable balloon rectal spacer used in radiation therapy for prostate

52-wk range ¥2,116-1,311

cancer. The acquisition is likely to expand the product lineup in the urology field, on

Market cap. ¥1,956b/US$12.3b

which the company is focusing, and our impression is positive.

Shares o/s 1,101m (ORD)

Rectal spacers help provide protection in prostate cancer radiation treatment Free float 95%

Avg. daily volume ('000) 6,551

Rectal spacers are a device intended to provide rectal protection during radiation therapy

for prostate cancer. Since the rectum and prostate are adjacent organs, radiation Avg. daily value (m) ¥10,064.4

exposure to the rectum can lead to adverse events such as bleeding and diarrhea in Common s/h equity (03/27E) ¥817b

some cases. The BioProtect Balloon Implant System received FDA Section 510(k) P/BV (03/27E) 2.4x